Share:

Posted on 03 October 2018

Professor Sir Greg Winter’s pioneering work using phage display for the directed evolution of antibodies has been recognised with a Nobel Prize. Professor Winter was jointly awarded the 2018 Nobel Prize in Chemistry along with Frances Arnold and George Smith.

The ground-breaking technology was developed by Professor Winter and the UK’s Medical Research Council in the 1990s via the company Cambridge Antibody Technology, which later became part of AstraZeneca.

Phage display, a platform technology that has delivered a number of the most successful antibody pharmaceuticals in the world, including AbbVie’s Humira® (adalimumab) which is used to treat rheumatoid arthritis, psoriasis and inflammatory bowel diseases. Phage display is also used to produce antibodies that can neutralise toxins, counteract autoimmune diseases and treat metastatic cancer. 

We are proud to have been involved in protecting this Nobel Prize winning technology. Seán Walton, partner in our life sciences team, worked with Professor Winter on patents for phage display.

You can read more about Professor Winter and his work here.

 

Seán Walton

Contact Seán Walton

Seán joined Mewburn Ellis LLP in 1990, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 1994. He joined the partnership in 1996. Seán handles patent work in the biotechnology field in particular immunology, antibody engineering, vaccines, diagnostics, medical devices, especially for drug delivery, and plant biotechnology. Seán has considerable experience of European opposition and appeal procedure and advises in strategic patent portfolio planning and analysis, including for applications and oppositions relating to several of the currently world-leading approved biopharmaceuticals. He has been involved in various UK and US litigation and interference proceedings. His clients include major international, US and European companies, including Big Pharma and biotechnology companies, also smaller growing and start-up companies in the USA, UK and Europe, and research institutions.

Related Posts